To accurately control the quality of HE cells derived using our normal iPSCs derived from AML patients upon EHT induction, we reassessed both the HE panels of phenotypes (a combination of FLK+CD34+CD43−CD235A− cells and our PFVCD45− cells). This evidence concerns the gene CD34 and acute myeloid leukemia.